An observational study in Characteristics Disease, Metastatic Cancer and Solid Tumor, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by University Hospital Augsburg · Observational
A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.
ALPS is a prospective observational trial to assess liquid biopsy as diagnostic tool in patients with various metastatic neoplasms. Liquid biopsy will be correlated not only with the tissue biopsy, but also to imaging modalities and classical tumor markers. In addition, the study aims to investigate clonal heterogeneity and evolution of different cancers during patient treatment courses. A third aspect of the study is to survey and assess patients' knowledge about biomarkers and personalized medicine in general and about liquid biopsy as a new diagnostic tool.
3,514 studies on the registry are indexed under Neoplasm Metastasis; 883 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 121 across 593 observational studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →University Hospital Augsburg is the lead sponsor of 24 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study population consists of patients with diagnosis of metastatic cancer at the University Hospital Augsburg.
Exclusion Criteria:
Correlation of tumor mutations between tissue biopsy (TBx) and liquid biopsy (LBx) at diagnosis
Correlation of tumor mutations between TBx and LBx at diagnosis with TBx as reference method based on PPA (positive percent agreement) and NPA (negative percent agreement)
Time frame: through study completion, an average of 3 years
Concordance between TBx and LBx at disease progression
Concordance between TBx and LBx at disease progression with TBx as reference method based on PPA (positive percent agreement) and NPA (negative percent agreement)
Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Investigation of tumor heterogeneity as a prognostic marker
Correlation of known and potential oncogenic drivers with imaging modalities based on morphological therapeutic response: ORR in classical entities and pools of tumor entities with ≥ 40 patient sample size
Time frame: through study completion, an average of 3 years
Correlation of known and potential oncogenic drivers in LBx with DCR
Correlation of known and potential oncogenic drivers with imaging modalities based on morphological therapeutic response: DCR in classical entities and pools of tumor entities with ≥ 40 patient sample size
Time frame: through study completion, an average of 3 years
Correlation of known and potential oncogenic drivers in LBx with OS
Correlation of presence of known and potential oncogenic drivers in LBx with OS per classical tumor entities and pools of tumor entities with ≥ 100 patient sample size
Time frame: through study completion, an average of 3 years
Role of a single numeric value (Shannon-Heterogeneity Index) at diagnosis as a surrogate marker for tumor heterogeneity
to evaluate the role of a single numeric value (Shannon-Heterogeneity Index) at diagnosis as a surrogate marker for tumor heterogeneity
Time frame: through study completion, an average of 3 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Augsburg